Prostate cancer: 12. The economic burden

CMAJ. Canadian Medical Association Journal

Volumn 160, Issue 5, 1999, Pages 685-690

  Grover, Steven A ^a,b   Zowall, Hanna ^a   Coupal, Louis ^a   Krahn, Murray D ^c  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MALE; PROSTATE CANCER; REVIEW;

EID: 0033537656     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Levy IG, Iscoe NA, Klotz LH. Prostate cancer: I. The descriptive epidemiology in Canada. CMAJ 1998;159(5):509-13.
2. Population projections for Canada, provinces and territories 1993-2016. Ottawa: Statistics Canada; 1993. Cat no 91-520.
3. Moore R, Mao Y, Zhang J, Clarke K. Economic burden of illness in Canada, 1993. Ottawa: Health Canada; 1997.
4. Cooper BS, Rice DP. The economic costs of illness revisited. Soc Secur Bull 1976;39:21-36.
5. Hodgson TA. The state of the art of cost-of-illness estimates. Adv Health Econ Health Serv Res 1983;4:129-64.
6. Robinson JC. Philosophical origins of the economic valuation of life. Millbank Q 1986;64:133-55.
7. Rice DP. Estimating the cost of illness. Washington: US Department of Health, Education and Welfare; 1966. Public Health Service, Health Economics Series 6.
8. O'Brien B, Viramontes JL. Willingness to pay: a valid and reliable measure of health state preference. Med Decis Making 1994;14:289-97.
9. Koopmanschap MA, Roijen LV, Bonneux L, Barendregt JJ. Current and future costs of cancer. Eur J Cancer 1994;30A:60-5.
10. Carlsson P, Hjertberg H, Jönsson B, Barenhorst E. The cost of prostatic cancer in a defined population. Scand J Urol Nephrol 1989;23:93-6.
11. Otnes B, Harvei S, Fossa SD. The burden of prostate cancer from diagnosis until death. Br J Urol 1995;76:587-94.
12. Denmeade SR, Isaacs JT. Prostate cancer: Where are we and where are we going? Br J Urol 1997;79(Suppl 1):2-7.
13. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, et al. Stage, age, comorbidity, and direct cost of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995;87:417-26.
14. 89Sr-chloride) in patients with prostate cancer metastatic to bone. Nucl Med Commun 1994;15:499-504.
15. Jones GW, Mettlin C, Murphy GP. Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990. J Am Coll Surg 1995;180:545-54.
16. Mettlin C, Jones GW, Murphy GP. Trends in prostate cancer care in the United States, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin 1993;43:83-91.
17. The PSA test in early detection of prostate cancer. Saskatoon: Health Services Utilization and Research Commission; 1995.
18. Bunting PS, Miyazaki JH, Goel V. Laboratory survey of prostate-specific antigen testing in Ontario. Clin Biochem 1998;31:47-9.
19. Variations in selected surgical procedures and medical diagnoses by year and region. In: Goel V, Williams JI, Anderson GM, Blackstien-Hirsch P, Fooks C, Naylor CD, editors. Patterns of health care in Ontario: the ICES practice atlas. 2nd ed. Ottawa: Canadian Medical Association; 1996. p. 51-146.
20. Resource intensity weights: summary of methodology. 1996/97. Ottawa: Canadian Institute for Health Information; 1996.
21. Manuel des médecins omnipraticiens. Quebec City: Régie de l'assurance-maladie du Québec; 1996.
22. Manuel des médecins spécialistes. Quebec City: Régie de l'assurance-maladie du Québec; 1996.
23. Schedule of benefits: physician services, 1992. Toronto: Ontario Ministry of Health; 1992.
24. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst 1996;88:166-73.
25. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy: time trends, geographic variation, and outcomes. JAMA 1993;269:2633-6.
26. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG Jr, Wennberg JE. A structured literature review of treatment for localized prostate cancer [published erratum in Arch Fam Med 1993;2:1030]. Arch Fam Med 1993;2:487-93.
27. To T, Iscoe N, Klotz L, Naylor CD. Orchiectomy and hormonal therapy of prostate cancer. Can J Urol 1995;2:109-15.
28. Anderson GM. An overview of the use of acute care hospitals, physician and diagnostic services and prescription drugs. In: Naylor CD, Anderson GM, Goel V, editors. Patterns of health care in Ontario: the ICES practice atlas. 1st ed. Ottawa: Canadian Medical Association; 1994. p. 21-45.
29. Canadian cancer statistics 1997. Toronto: National Cancer Institute of Canada; 1997.
30. Morrison HI, MacNeill IB, Miller D, Levy I, Xie L, Mao Y. The impending Canadian prostate cancer epidemic. Can J Public Health 1995;86:274-8.
31. Norland JA. Focus on Canada: profile of Canada's seniors. Ottawa: Statistics Canada; 1994. Cat no 96-312E.
32. Drummond MF. Cost-of-illness studies: A major headache? Pharmacol Econ 1992;2:1-4.
33. Shiell A, Gerrard K, Donaldson C. Cost of illness studies: An aid to decision-making? Health Policy 1987;8:317-23.
34. Hodgson TA. Cost of illness studies: No aid to decision-making? Health Policy 1989;11:57-60.
35. Gold MR, Russell LB, Siegel JE, Weinstein MC, editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996.
36. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer: a decision analytic view. JAMA 1994;272:781-6.
37. Optenberg SA, Thompson IM. Economics of screening for carcinoma of the prostate. Urol Clin North Am 1990;17:719-37.
38. Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs. Montreal: Conseil d'évaluation des technologies de la santé du Québec; 1995.
39. Littrup PJ, Goodman AC, Mettlin CJ. The benefit and cost of prostate cancer early detection. CA Cancer J Clin 1993;43:134-49.
40. Coley CM, Barry MJ, Fleming C, Fahs MC, Mulley AG. Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. Ann Intern Med 1997;126:468-79.
41. Cantor SB, Spann SJ, Volk RJ, Cardenas MP, Warren MM. Prostate cancer screening: a decision analysis. J Fam Pract 1995;41:33-41.
42. Epstein JI, Walsh PC, Sanfilippo F. Clinical and cost impact of second-opinion pathology: review of prostate biopsies prior to radical prostatectomy. Am J Surg Pathol 1996;20:851-7.
43. Perrotti M, Gentle DL, Barada JH, Wilbur HJ, Kaufman RPJ. Mini-laparotomy pelvic lymph node dissection minimizes morbidity, hospitalization and cost of pelvic lymph node dissection. J Urol 1996;155:986-8.
44. Forman HP, Fox LA, Glazer HS, McClennan BL, Anderson DC, Sagel SS. Chest radiography inpatients with early stage prostatic carcinoma. Effect on treatment planning and cost analysis. Chest 1994;106:1036-41.
45. Forman HP, Heiken JP, Brink JA, Glazer HS, Fox LA, McClennan BL. CT screening for comorbid disease in patients with prostatic carcinoma: Is it cost-effective? Am J Roentgenol 1994;162:1125-8.
46. Licht MR, Klein EA. Early hospital discharge after radical retropubic prostatectomy: impact on cost and complication rate. Urology 1994;44:700-4.
47. Hillner BE, McLeod DG, Crawford ED, Bennett CL. Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology 1995;45(4):633-40.
48. Bennett CL, Matchar D, McCrory D, McLeod DG, Crawford ED, Hillner BE. Cost-effective models for flutamide for prostate carcinoma patients. Are they helpful to policy makers? Cancer 1996;77:1854-61.
49. Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Smith TJ, Warde P, et al. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol 1998;16:2272-9.